Emedastine fumarate composition and preparation method thereof

By introducing stearic acid as a plasticizer into emestin fumarate extended-release capsules, the problem of dose dumping in ethanol medium was solved, achieving a release curve similar to the reference formulation and higher safety and efficacy.

CN118903147APending Publication Date: 2024-11-08HUNAN PUDAO PHARM TECH CO LTD
View PDF 0 Cites 3 Cited by

Patent Information

Application Number
CN202410954708.4
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-17
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

Existing emesitine fumarate extended-release capsules exhibit dose dumping in ethanol media, leading to risks to drug safety and efficacy, and making it difficult to approximate the reference formulation.

Method used

Stearic acid was used as a plasticizer to adjust the composition of sustained-release capsules. Emestin fumarate sustained-release capsules were prepared by fluidized bed coating technology to improve dosage dispensing performance.

Benefits of technology

The safety and efficacy of the sustained-release capsules were improved, the release curve was consistent with the reference formulation, and the dose decay in ethanol medium was significantly reduced, with good long-term stability.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118903147A_ABST
    Figure CN118903147A_ABST
Patent Text Reader

Abstract

The invention discloses an emedastine fumarate composition and a preparation method thereof, the emedastine fumarate composition comprises emedastine fumarate and a plasticizer, and the plasticizer is stearic acid. The stearic acid is introduced into the emedastine fumarate composition, so that the pouring performance of the composition can be improved, and the safety and effectiveness of the preparation are improved. The emedastine fumarate composition has a good slow-release effect, has a release curve consistent with that of a reference preparation, is equivalent to that of a reference preparation BE, and plays a role in replacing the reference preparation.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of pharmaceutical preparations, and specifically relates to an emedastine fumarate composition and a preparation method thereof. Background Art

[0002] Emedastine fumarate is a second-generation histamine H1 receptor antagonist with a specific affinity for H1 receptors. It is mainly used clinically to treat allergic rhinitis and chronic urticaria. Compared with similar drugs, emedastine fumarate has the characteristics of high efficacy, few side effects, good tolerance, and no cardiotoxicity. In particular, it has a small central nervous system sedative effect and no side effects such as drowsiness after use. Therefore, it is very popular among patients.

[0003] Sustained-release preparations belong to the second generation of current pharmaceutical preparations. Due to the absorption characteristics of ordinary preparations, which cause the phenomenon of blood drug concentration peaks, when the blood drug concentration is high or the physiological conditions change, it is easy for the blood drug concentration to exceed the toxic amount of the drug, resulting in serious toxic and side effects. Sustained-release preparations release the drug slowly, and the blood concentration is stable. They are much superior to ordinary preparations in prolonging the action time and reducing toxic and side effects.

[0004] Emedastine Fumarate Sustained Release Capsules are antihistamine drugs. They were first launched in Japan in August 1993 in 1mg and 2mg specifications under the trade name "Remicut". They were first developed and produced by Kowa Co., Ltd. and are used to treat allergic rhinitis, urticaria, eczema, dermatitis, pruritus and prurigo.

[0005] Regarding the ethanol dose dumping of drugs, the "Technical Guidelines for Pharmaceutical Research on Alcohol Dose Dumping Tests for Oral Modified-Release Preparations of Chemical Generic Drugs" issued by the Drug Review Center of the State Drug Administration in November 2022 mentioned: Ethanol dose dumping refers to the sudden release of modified-release preparations caused by taking alcoholic beverages with drugs. Alcoholic beverages may lead to accelerated drug release and changes in systemic exposure, causing safety and efficacy risks of drugs. Ethanol dose dumping studies are conducted, that is, in vitro tests are used to study the possibility of ethanol causing drug dose dumping in vivo. In the in vitro evaluation, drug release in media with different ethanol concentrations needs to be studied. It is recommended to give priority to 0.1N or pH1.2 hydrochloric acid solution as the dissolution medium, and the ethanol addition concentrations are 0%, 5%, 20%, and 40%. Result analysis: If both generic and reference preparations have ethanol dose dumping and it cannot be avoided, it should be made clear that the dose dumping risk of generic preparations should generally not be higher than that of reference preparations.

[0006] There are few studies on emedastine fumarate sustained-release capsules in China. The main one is Sichuan Defeng Pharmaceutical Co., Ltd., which applied for a patent for the preparation process of emedastine fumarate sustained-release capsules (CN 111643485 A) and published a related paper in "China Pharmaceutical Industry" (Zhang Hongmo et al., Preparation process and in vitro release of emedastine fumarate sustained-release capsules [J], China Pharmaceutical Industry, 2023: 5 (32): 61-64). In the patent and paper, the in vitro release curve of emedastine fumarate sustained-release capsules was basically consistent with that of the reference preparation through process improvement and exploration of the prescription ratio of the sustained-release layer. Through research, it was found that although the use of its method and formulation can make the in vitro release curve basically consistent with that of the reference preparation, it is difficult to achieve dose dumping close to that of the reference preparation; therefore, there are potential risks to drug safety and efficacy by referring to its method and formulation.

[0007] By using the original preparation (reference preparation) for a dose dumping test, it was found that the dumping in 20% ethanol pH 1.2 was about 9% in 2 hours, posing a potential risk to drug safety and efficacy. Summary of the invention

[0008] The purpose of the present invention is to provide an emedastine fumarate composition with good safety, controllable quality and stable drug release and a preparation method thereof.

[0009] The emedastine fumarate composition provided by the present invention adopts the following technical scheme:

[0010] An emedastine fumarate composition comprises: emedastine fumarate and a plasticizer, wherein the plasticizer is stearic acid.

[0011] Preferably, the amount of the plasticizer used is 0.20 to 0.75 times the mass of emedastine fumarate.

[0012] In the present invention, by using stearic acid as a plasticizer, the dose dumping problem of the emedastine fumarate composition can be further improved while ensuring the release performance and quality of the drug, thereby ensuring the safety of the drug.

[0013] Preferably, the emedastine fumarate composition is a sustained-release capsule.

[0014] A sustained-release emedastine fumarate capsule comprises: emedastine fumarate, a pill core, an adhesive, a plasticizer, a pore-forming agent, an anti-adhesive agent, and a retardant; wherein the plasticizer is stearic acid.

[0015] Preferably, the emedastine fumarate sustained-release capsules, measured by weight, comprise:

[0016] 0.55-1.40 parts of emedastine fumarate; 3.0-4.5 parts of binder; 0.6-1.1 parts of pore-forming agent; 0.1-0.2 parts of anti-adhesive agent; 88-92 parts of blank pill core; 2.0-2.9 parts of retarder; 0.3-0.4 parts of plasticizer.

[0017] Preferably, the binder is one or more of hydroxypropyl cellulose, hydroxypropyl methylcellulose, hydroxyethyl cellulose, and povidone; the pore-forming agent is one or more of hydroxypropyl cellulose, hydroxypropyl methylcellulose, hydroxyethyl cellulose, povidone, and sucrose; the anti-adhesive agent is one or more of magnesium stearate, talc, calcium stearate, and sodium stearyl fumarate; the blank pill core is one of a sucrose pill core and a microcrystalline cellulose pill core; the retarder is one of ethyl cellulose, cellulose acetate, and polyacrylic acid resin.

[0018] A method for preparing emedastine fumarate sustained-release capsules comprises the following steps:

[0019] 1) Preparation of drug-coated pellets: preparing a coating solution with a binder and emedastine fumarate; using blank pellet cores as carriers, bottom spray coating is performed in a fluidized bed to obtain drug-coated pellets;

[0020] 2) Preparation of sustained-release layer pellets: prepare a sustained-release layer coating solution by mixing a pore-forming agent, a retardant and stearic acid; take the upper drug layer pellets, place them in a fluidized bed for bottom spray coating, and obtain sustained-release layer pellets.

[0021] 3) Preparation of sustained-release capsules: The micropellets and the anti-adhesive agent are mixed evenly and then filled into hollow capsules to obtain emedastine fumarate sustained-release capsules.

[0022] The emedastine fumarate composition and the emedastine fumarate sustained-release capsule are used in preparing a medicament for treating or preventing the following diseases or conditions: allergic conjunctivitis, eczema, urticaria, allergic dermatitis, and allergic rhinitis.

[0023] Beneficial effects of the present invention:

[0024] 1) The present invention can improve the dose dumping performance of the composition by introducing stearic acid into the composition of emedastine fumarate. Compared with the reference preparation, the dose dumping of the composition of the present invention is further improved, which helps to improve the safety and effectiveness of the preparation.

[0025] 2) The emedastine fumarate composition of the present invention has a good sustained-release effect, has a consistent release curve with the reference preparation, is BE equivalent to the reference preparation, and has better safety and effectiveness, and can replace the reference preparation.

[0026] 3) The emedastine fumarate composition of the present invention has good long-term storage stability. BRIEF DESCRIPTION OF THE DRAWINGS

[0027] Figure 1 Release curves of the emedastine fumarate sustained-release capsules prepared in Example 1 and the reference preparation.

[0028] Figure 2 Release curves of emedastine fumarate sustained-release capsules prepared in Comparative Example 1 and the reference preparation.

[0029] Figure 3 Release curves of emedastine fumarate sustained-release capsules prepared in Comparative Example 2 and the reference preparation.

[0030] Figure 4 Release curves of the emedastine fumarate sustained-release capsules prepared in Examples 2 and 3 and the reference preparation.

[0031] Figure 5 Release curves of the emedastine fumarate sustained-release capsules prepared in Examples 4 and 5 and the reference preparation.

[0032] Figure 6 Release curves of the emedastine fumarate sustained-release capsules prepared in Examples 6 and 7 and the reference preparation.

[0033] Figure 7 Release curves of the emedastine fumarate sustained-release capsules prepared in Examples 8 and 9 and the reference preparation. DETAILED DESCRIPTION

[0034] The present invention is further described in detail below with reference to the embodiments.

[0035] The reference preparation in the present invention is Emedastine Fumarate Sustained Release Capsules produced by Kowa Co., Ltd. of Japan.

[0036] The particle size distribution of the sugar pill core used in the embodiment of the present invention is 850-1000 μm.

[0037] The release curve and dose dumping analysis method in the present invention mainly refer to the Japanese Orange Book and the Chinese Pharmacopoeia 2020 Edition Part IV, and the specific methods are as follows: (1) The release curve method is: using 900 ml of hydrochloric acid solution (pH 1.2) as the solvent, the rotation speed is 50 rpm, the sampling volume and the rehydration volume are 10 ml, the sampling points are 0.25, 0.5, 1, 1.5, 2, 4, 6, 9, 12h, and the release is determined according to the proposed chromatographic conditions. (2) Dose dumping analysis method: using 900 ml of 20% ethanol hydrochloric acid solution (pH 1.2) as the solvent, the rotation speed is 50 rpm, the sampling volume and the rehydration volume are 10 ml, the sampling points are 0.25, 0.5, 1, 1.5, 2h, and the release is determined according to the proposed chromatographic conditions.

[0038] The stability test method mainly refers to Part IV of the 2020 edition of the Chinese Pharmacopoeia; stability test conditions: accelerated 40°C (humidity 75%) and long-term 30°C (humidity 65%).

[0039] Example 1

[0040] The composition of the emedastine fumarate sustained-release capsules of Example 1 can be seen in Table 1:

[0041] Table 1

[0042] Components Example 1 (parts by weight) Emedastine Fumarate 1.39 Hydroxypropylcellulose (binder) 3.47 Hydroxypropyl cellulose (porogen) 1.22 Magnesium Stearate 0.15 Sucrose pellets 90.72 Ethyl cellulose 2.70 Stearic acid 0.35

[0043] The specific preparation method is:

[0044] Drug layer pellets: 3.47 parts of hydroxypropyl cellulose and 1.39 parts of emedastine fumarate API were added to the solvent (purified water) to prepare a coating solution to obtain the drug layer coating solution. 90.72 parts of sucrose pellet cores were placed in a FLZB-50 Chuangzhi fluidized bed for bottom spray coating. After coating, the pellets were dried and sieved to obtain drug layer pellets.

[0045] Sustained-release layer pellets: Add 1.22 parts of hydroxypropyl cellulose, 2.70 parts of ethyl cellulose and stearic acid to the solvent (ethanol) to obtain the sustained-release layer coating solution. Take the upper drug layer pellets and place them in the FLZB-50 Chuangzhi fluidized bed for bottom spray coating. After the coating is completed, dry and sieve to obtain the sustained-release layer pellets.

[0046] Sustained-release capsules: Mix the micropellets with 0.15 parts of magnesium stearate and fill them into empty gelatin capsules to obtain emedastine fumarate sustained-release capsules.

[0047] The emedastine fumarate sustained-release capsules prepared in this example were tested for release performance (pH = 1.2), dose dumping (20% ethanol, pH = 1.2), stability, and in vivo release pre-experiments. The sustained-release curve shows that Figure 1 , the dose dumping can be seen in Table 2, the stability can be seen in Table 3, and the in vivo release preliminary experiment can be seen in Table 4.

[0048] Table 2

[0049]

[0050] Table 3

[0051]

[0052] Table 4

[0053]

[0054] from Figure 1It can be seen that the release curve of the emedastine fumarate sustained-release capsules prepared in this embodiment has a similarity factor F2 of 88.5 with that of the reference preparation, which is greater than 50, indicating that the sustained-release capsules in this embodiment have a release curve similar to that of the reference preparation. As can be seen from Table 2, the dose dumping of the emedastine fumarate sustained-release capsules prepared in this embodiment is 7.4% lower than that of the reference preparation. The reference preparation has a small amount of dumping, while this embodiment has basically no dumping. The safety and effectiveness of the emedastine fumarate sustained-release capsules prepared in this embodiment are better than the reference preparation.

[0055] As can be seen from Table 3, the emedastine fumarate sustained-release capsules prepared in this embodiment have no significant change in release rate after being observed under accelerated and long-term conditions for 3 months, and have good stability. As can be seen from Table 4, based on human data, the emedastine fumarate sustained-release capsules prepared in this embodiment are also completely bioequivalent to the reference preparation.

[0056] Comparative Examples 1-2

[0057] The compositions of the emedastine fumarate sustained-release capsules in Comparative Examples 1-2 can be seen in Table 5.

[0058] Table 5

[0059] Components Comparative Example 1 (parts by weight) Comparative Example 2 (parts by weight) Emedastine Fumarate 1.39 1.39 Hydroxypropylcellulose (binder) 3.47 3.47 Hydroxypropyl cellulose (porogen) 1.57 1.22 Magnesium Stearate 0.15 0.15 Sucrose pellets 90.72 90.72 Ethyl cellulose 2.70 2.70 Triethyl citrate / 0.35

[0060] The preparation methods in Comparative Examples 1 and 2 are basically the same as those in Example 1.

[0061] The release curves of Comparative Example 1 and Comparative Example 2 are as follows Figure 2 and Figure 3 The data on dose dumping can be found in Table 6.

[0062] Table 6

[0063]

[0064]

[0065] from Figure 2 As can be seen from Table 6, the sustained-release capsule in Comparative Example 1 does not add plasticizer, and its release curve in pH 1.2 medium has a similarity factor F2 value of 65.2 with the reference preparation, which is greater than 50, indicating that the sustained-release capsule in Comparative Example 1 has a similar release curve to the reference preparation, but its F2 value has dropped by more than 20% compared with Example 1, indicating that the plasticizer has an effect on the release curve of the sustained-release capsule. In 20% ethanol pH 1.2 medium, the dose dumping of the sustained-release capsule in Comparative Example 1 is 20.2%, the reference preparation is 9.0%, and the Example 1 is only 1.6%, indicating that the dose dumping of Comparative Example 1 is more serious than that of the reference preparation without adding plasticizer, and there may be problems with drug safety.

[0066] from Figure 3 As can be seen from Table 6, the sustained-release capsule in Comparative Example 2 added triethyl citrate plasticizer, and the similarity factor F2 value of its release curve in pH1.2 medium and the reference preparation was 77.5, which was greater than 50, indicating that the sustained-release capsule in Comparative Example 2 was similar to the reference preparation in release curve. In 20% ethanol pH1.2 medium, the dose dumping was 16.6%, the reference preparation was 9.0%, and the Example 1 was only 1.6%, indicating that the dose dumping of Comparative Example 2 using triethyl citrate as a plasticizer was improved compared with Comparative Example 1, but its dose dumping was higher than the reference preparation and Example 1; indicating that the plasticizing effect of triethyl citrate was not good, and failed to effectively improve the dose dumping problem of emedastine fumarate sustained-release capsules.

[0067] Embodiment 2-3

[0068] The compositions of the emedastine fumarate sustained-release capsules in Examples 2-3 can be seen in Table 7.

[0069] Table 7

[0070]

[0071]

[0072] The preparation methods of Examples 2 and 3 are basically the same as those of Example 1.

[0073] The curves in Examples 2 to 3 are as follows Figure 4 The data on dose dumping can be seen in Table 8.

[0074] Table 8

[0075]

[0076] from Figure 4 As can be seen from Table 8, the similarity factor F2 values ​​of the release curves of the sustained-release capsules in Examples 2 and 3 in pH 1.2 medium and the reference preparation are 77.0 and 73.6, respectively, which are greater than 50, indicating that the release curves of the sustained-release capsules in Examples 2 and 3 are similar to those of the reference preparation. Compared with Example 1, the amount of plasticizer in Example 2 is reduced, and its dose dumping is increased compared with Example 1, but still lower than the reference preparation; compared with Example 1, the amount of plasticizer in Example 3 is increased, and its dose dumping is further reduced compared with Example 1.

[0077] In general, the dose dumping of the sustained-release capsules prepared in Examples 2 and 3 is lower than that of the reference preparation, and the sustained-release capsules prepared in Example 3 are even lower than that in Example 1, indicating that the safety and effectiveness of the sustained-release capsules in Examples 2 and 3 should be better than those in the reference preparation; however, in Examples 2 and 3, the F2 values ​​are more than 10% lower than that in Example 1. Although their release properties are still similar to those of the reference preparation, it indicates that the amount of plasticizer used will affect their release properties.

[0078] Embodiment 4-5

[0079] The compositions of the emedastine fumarate sustained-release capsules in Examples 4 to 5 can be seen in Table 9.

[0080] Table 9

[0081] Components Example 4 Example 5 Emedastine Fumarate 0.70 0.57 Hydroxypropylcellulose (binder) 3.50 4.20 Hydroxypropyl cellulose (porogen) 1.42 1.37 Magnesium Stearate 0.15 0.15 Sucrose pellets 91.13 90.50 Ethyl cellulose 2.75 2.85 Stearic acid 0.35 0.36

[0082] The preparation methods of Examples 4 and 5 are basically the same as those of Example 1.

[0083] The curves in Examples 4 to 5 are as follows Figure 5 The data on dose dumping can be seen in Table 10.

[0084] Table 10

[0085]

[0086] from Figure 5 As can be seen from Table 10, the release curves of the sustained-release capsules prepared in Examples 4 and 5 in a pH 1.2 medium have similarity factors F2 values ​​of 88.9 and 89.4, respectively, with those of the reference preparation, which are greater than 50, indicating that the release curves of the sustained-release capsules in Examples 4 and 5 are similar to those of the reference preparation. The dose dumping in Examples 4 and 5 is lower than that of the reference preparation, indicating that the safety and efficacy of Examples 4 and 5 should be better than that of the reference preparation.

[0087] Embodiment 6-7

[0088] The compositions of the emedastine fumarate sustained-release capsules in Examples 6 to 7 can be seen in Table 11.

[0089] Table 11

[0090]

[0091]

[0092] The preparation method of Examples 6-7 is basically the same as that of Example 1

[0093] The curves in Examples 6 to 7 are as follows Figure 6 , the data on dose dumping can be seen in Table 12.

[0094] Table 12

[0095]

[0096] from Figure 6As can be seen from Table 12, the release curves of the sustained-release capsules prepared in Examples 6 and 7 in a pH 1.2 medium have similarity factors F2 values ​​of 89.8 and 85.3, respectively, with those of the reference preparation, which are greater than 50, indicating that the release curves of the sustained-release capsules in Examples 6 and 7 are similar to those of the reference preparation. The dose dumping of the sustained-release capsules prepared in Examples 6 and 7 is lower than that of the reference preparation, and the safety and efficacy of the sustained-release capsules prepared in Examples 6 and 7 are better than those of the reference preparation.

[0097] Embodiments 8 to 9

[0098] The compositions of the emedastine fumarate sustained-release capsules in Examples 8 to 9 can be seen in Table 13.

[0099] Table 13

[0100]

[0101]

[0102] The preparation methods of Examples 8 and 9 are basically the same as those of Example 1.

[0103] The curves in Examples 8 to 9 are as follows Figure 7 The data on dose dumping can be seen in Table 14.

[0104] Table 14

[0105]

[0106] from Figure 7 As can be seen from Table 14, the similarity factor F2 values ​​of the release curves of Examples 8 and 9 in pH 1.2 medium and the reference preparation are 91.4 and 86.8, respectively, which are greater than 50, indicating that the release curves of the sustained-release capsules in Examples 8 and 9 are similar to those of the reference preparation. The dose dumping of the sustained-release capsules prepared in Examples 8 and 9 is lower than that of the reference preparation, and the safety and efficacy of the sustained-release capsules prepared in Examples 8 and 9 are better than those of the reference preparation.

Claims

1. An emedastine fumarate composition, characterized in that: The invention comprises: emedastine fumarate and a plasticizer, wherein the plasticizer is stearic acid.

2. The emedastine fumarate composition according to claim 1, characterized in that The amount of plasticizer used is 0.20 to 0.75 times the mass of emedastine fumarate.

3. The emedastine fumarate composition according to claim 1 or 2, characterized in that: It is a sustained-release capsule.

4. A sustained-release emedastine fumarate capsule, characterized in that: The invention comprises: emedastine fumarate, blank pill core, adhesive, plasticizer, pore-forming agent, anti-adhesive agent and retardant; wherein the plasticizer is stearic acid.

5. The emedastine fumarate sustained-release capsule according to claim 4, characterized in that: Calculated by weight, the composition comprises: 0.55-1.40 parts of emedastine fumarate; 3.0-4.5 parts of adhesive; 0.6-1.1 parts of pore-forming agent; 0.1-0.2 parts of anti-adhesive agent; 88-92 parts of blank pill core; 2.0-2.9 parts of retarder; and 0.3-0.4 parts of plasticizer.

6. A method for preparing the emedastine fumarate sustained-release capsules according to any one of claims 4 to 5, characterized in that: The following steps are involved: 1) Preparation of drug-coated pellets: preparing a coating solution with a binder and emedastine fumarate; using blank pellet cores as carriers, bottom spray coating was performed in a fluidized bed to obtain drug-coated pellets; 2) Preparation of sustained-release layer pellets: preparing a sustained-release layer coating solution by mixing a pore-forming agent, a retardant and stearic acid; taking the upper drug layer pellets, placing them in a fluidized bed for bottom spray coating, and obtaining sustained-release layer pellets; 3) Preparation of sustained-release capsules: The micropellets and the anti-adhesive agent are mixed evenly and then filled into hollow capsules to obtain emedastine fumarate sustained-release capsules.

7. Use of the emedastine fumarate composition according to claim 1 or 2 in the preparation of a medicament for treating or preventing a disease or condition selected from the following: allergic conjunctivitis, eczema, urticaria, allergic dermatitis, allergic rhinitis.

8. Use of the emedastine fumarate composition and the emedastine fumarate sustained-release capsule according to claim 3 or 4 in the preparation of a medicament for treating or preventing the following diseases or conditions: allergic conjunctivitis, eczema, urticaria, allergic dermatitis, allergic rhinitis.

Citation Information

Cited By

  • Emedastine fumarate preparation and preparation method thereof

    CN119139256A

  • Emedastine Difumarate Preparation and Its Preparation Method

    CN119139256B

  • Emedastine fumarate sustained release composition, process for its preparation and use thereof

    CN122911927A